A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00114946|
Recruitment Status : Terminated
First Posted : June 21, 2005
Last Update Posted : May 29, 2006
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: Avastin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||800 participants|
|Official Title:||A Randomized, Open-Label Trial Comparing Two Avastin (Bevacizumab)-Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer|
|Study Start Date :||May 2005|
|Study Completion Date :||December 2007|
- To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.
- To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00114946
|Study Director:||Mary Sugrue, M.D.||Genentech, Inc.|